Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating the Difficulties of Nutrition During Cancer Care as a Nurse

April 26, 2025
By Claudia Aguilar Clancy, RN, FNP-C
News
Video
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.

Claudia Aguilar Clancy, RN, FNP-C, stated that addressing the nutritional needs of patients with various types of cancer can be difficult because it depends on several things such as where the tumor developed and if the patient requires a feeding tube.

During a conversation with CancerNetwork® at the 2025 Oncology Nursing Society (ONS) Congress, Clancy, a nurse practitioner at Texas Oncology, discussed the complexities of helping patients meet their dietary and nutritional needs during cancer care. For those that have to use a feeding tube, soft foods and pureed foods are commonly used; Clancy stated that there is a big list of high-protein and soft food options she shows her patients so they get “the best fuel possible.”

Additionally, the type of treatment that a patient receives also factors into what they can and cannot eat. If a patient receives radiation therapy directed at the gastrointestinal tract, Clancy will not serve that patient foods with high amounts of fiber because it may lead to more diarrhea or nausea.

The goal is not only to supply food that mitigates adverse effects (AEs) but also provide a patient with the strength to get through their treatments.


Transcript:

I love my head and neck population. They are challenging, and they’re unique because it depends on where the tumor starts, and it depends on where the feeding tube is going to go. Is it going to be in the stomach? Is it going to be in the jejunum—[also known as] the J tube. If they can eat some [food], normally, we assess, “Okay, do they have a feeding tube? Can they eat orally?” If they cannot, then that’s when the formulas are obtained, and [they get] soft foods and pureed foods. I give them a big list of all those [items] that are high protein but soft. They’re getting the best fuel possible.

Then we have our patients who don’t have a feeding tube, and those patients can eat. During radiation, depending on where the radiation is, if it’s a [gastrointestinal] tract radiation location, then we have to think about lower fiber [foods], even though fiber is good, but at that particular time, it can cause more diarrhea and more of those [AEs] that we don’t want them to have. It could also cause a little bit more nausea and things like that.

We have to see what the diagnosis is to tailor the nutrition part of it so that they can be successful, and have low [AEs] because of food, but then also have food that is going to help them get through the radiation. Food is powerful, and they need fuel. It’s a challenge because, at that time, they don’t want to eat, but they have to eat.

Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Related Content
Advertisement

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

David J. Portman;Timothy Pluard;Jane L. Meisel, MD;Kelly Shanahan;Sarah Sammons, MD;Elizabeth Attias
April 26th 2025
Article

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.


Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Tim Cortese
April 24th 2025
Article

Polypharmacy, medication list errors, and drug-drug interactions were all observed in patients with cancer receiving oral anticancer drugs.

Related Content
Advertisement

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

David J. Portman;Timothy Pluard;Jane L. Meisel, MD;Kelly Shanahan;Sarah Sammons, MD;Elizabeth Attias
April 26th 2025
Article

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors

Tim Cortese
April 24th 2025
Article

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-G12D mutation.


Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care

Tim Cortese
April 24th 2025
Article

Polypharmacy, medication list errors, and drug-drug interactions were all observed in patients with cancer receiving oral anticancer drugs.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.